US 2003/0198976 A1Published application

Novel human G-protein coupled receptor, HGPRBMY14, related to the orphan GPCR, GPR73

OwnerJohn N. Feder, Chandra S. Ramanathan +6inventors

InventorsJohn N. Feder, Chandra S. Ramanathan, Thomas C. Nelson, Michael G. Kornacker, Rolf-Peter Ryseck, Angela Cacace, Lauren E. Barber, David K. Bol

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention provides novel polynucleotides encoding HGPRBMY14 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY14 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Claims26

Dependent claims

An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:PTA-3745, which is hybridizable to SEQ ID NO:1;
(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:PTA-3745, which is hybridizable to SEQ ID NO:1;
(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:PTA-3745, which is hybridizable to SEQ ID NO:1;
(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included. in ATCC Deposit No:PTA-3745, which is hybridizable to SEQ ID NO:1;
(e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No:PTA-3745, which is hybridizable to SEQ ID NO:1, having biological activity;
(f) an isolated polynucleotide comprising nucleotides 1289 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
(g) an isolated polynucleotide comprising nucleotides 1286 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
(h) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

6 more elements

A method for treating, or ameliorating a medical condition with the polypeptide provided as SEQ ID NO:2, or a modulator thereof, wherein the medical condition is a member of the group consisting of:

a disorder related to aberrant NF-KB activity;
disorders related to aberrant IkBa expression or activity;
a disorder directly linked to aberrant neuropeptide Y receptor activity;
an eating or appetite disorder;
a disorder linked to aberrant DNA synthesis;
a male reproductive disorder;
testicular cancer;
autoimmune diorders;
disorders related to hyper immune activity;
hypercongenital conditions;
birth defects;
necrotic lesions;
wounds;
disorders related to aberrant signal transduction;
immuno compromised conditions;
HIV infection;
proliferative disorder of the skin;
melanoma;
fetal lung disorder;
proliferative fetal lung disorder;
disorder of the breast;
proliferative disorder of the breast;
breast cancer;
in addition to other proliferative diseases and/or disorders;
such as cancers;
in addition to other conditions referenced herein or known to be associated with the reproductive system;
disorders related to abnormal populations of cells or tissues in the G1 phase of the cell cycle;
disorders related to abnormal populations of cells or tissues in the S phase of the cell cycle;
disorders related to abnormal populations of cells or tissues in the G2 phase of the cell cycle;
disorders related to abnormal populations of cells or tissues in the M phase of the cell cycle;
disorders related to aberrant smooth muscle contraction;
and disorders related to aberrant angiogenesis.

29 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/295,693Filed 14 Nov 2002
Priority: 5 Feb 2001
Published: 23 Oct 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

C07K 14/705
From animals; from humans: receptors; Cell surface antigens; Cell surface determinants
A61K 38/00
Medicinal preparations containing peptides
C07K
Peptides
A61K
Medicines and medical preparations

Family

Application60/266,525Us provisional application · filed 5 Feb 2001
Application60/329,897Us provisional application · filed 16 Oct 2001
Application10/067,649Continuation in part · filed 5 Feb 2002
Application10/295,693Continuation in part · filed 14 Nov 2002
US 2003/0100057 A1Published application
US 2003/0198976 A1This patent

From the US filing history. Foreign family members aren’t listed.